18.07.2025 • Topics

ISPE Good Practice Guide: Validation 4.0

The Validation 4.0 Guide provides a comprehensive approach to ensuring product quality and patient safety throughout a pharmaceutical product's lifecycle. A Holistic Control Strategy (HCS) in this context means moving beyond traditional, static, upfront and localized validation controls to a dynamic, data-driven, and continuous approach to managing risks and quality along the broader value chain.

Guide cover
© ISPE

This Guide is intended to be an early introduction into modern validation thinking in an increasingly digital world that offers new capabilities for managing and controlling manufacturing processes. The structure starts with an overview of methodology considerations, covers foundational enablers, required capabilities and a section on real-life case studies that have been selected to explain aspects to consider when adopting Validation 4.0 in practice.

A Maturity Self-Assessment Tool is included in the E-Reader (under Materials/Supplements) as a downloadable Microsoft Excel file to purchasers of the Guide. See the FAQ for accessing instructions.

The primary intention behind this self-assessment tool is to empower organizations to accurately characterize their current state of maturity and, more importantly, identify specific areas where targeted improvements can be made.

ISPE Good Practice Guide: Validation 4.0

Click here to purchase the guide.

Access Here!

Company

Logo:

International Society for Pharmaceutical Engineering (ISPE)

6110 Executive Blvd.
20852 North Bethesda
US

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read